Quantifying Clinical Utility of Enzalutamide for Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer
- PMID: 35985008
- DOI: 10.1200/JCO.22.01084
Quantifying Clinical Utility of Enzalutamide for Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer
Comment in
-
Reply to R. Sun et al.J Clin Oncol. 2022 Dec 20;40(36):4279-4280. doi: 10.1200/JCO.22.01470. Epub 2022 Aug 19. J Clin Oncol. 2022. PMID: 35985006 No abstract available.
Comment on
-
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer.J Clin Oncol. 2022 May 20;40(15):1616-1622. doi: 10.1200/JCO.22.00193. Epub 2022 Apr 14. J Clin Oncol. 2022. PMID: 35420921 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical